AONC — American Oncology Network Income Statement
0.000.00%
- $304.74m
- $408.28m
- $1.76bn
- 22
- 55
- 65
- 45
Annual income statement for American Oncology Network, fiscal year end - December 31st, USD millions except per share, conversion factor applied.
2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | 2024 December 31st | |
---|---|---|---|---|---|
Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
Source: | PROSPECTUS | PROSPECTUS | PROSPECTUS | 10-K | 10-K |
Standards: | USG | USG | USG | USG | USG |
Status: | Final | Final | Final | Final | Final |
Revenue | |||||
Total Revenue | 725 | 944 | 1,150 | 1,279 | 1,759 |
Cost of Revenue | |||||
Gross Profit | 77.4 | 94.2 | 95.5 | 82.8 | 118 |
Selling / General / Administrative Expenses | |||||
Depreciation and Amortization | |||||
Unusual Expense / Income | |||||
Total Operating Expenses | 703 | 943 | 1,144 | 1,328 | 1,777 |
Operating Profit | 22.1 | 0.911 | 5.57 | -49.2 | -17.4 |
Total Net Non Operating Interest Income / Expense | |||||
Other Net Non Operating Costs | |||||
Net Income Before Taxes | 21.2 | 0.355 | 2.59 | -62.5 | -24.6 |
Provision for Income Taxes | |||||
Net Income After Taxes | 22 | -0.105 | 2.59 | -62.9 | -27.1 |
Minority Interest | |||||
Equity in Affiliates | |||||
Net Income Before Extraordinary Items | |||||
Net Income | 0 | 0 | 0 | -5.54 | -3.97 |
Adjustments to Net Income | |||||
Income Available to Common Shareholders Excluding Extraordinary Items | |||||
Income Available to Common Shareholders Including Extraordinary Items | |||||
Diluted Net Income | 0 | 0 | 0 | -9.12 | -9.52 |
Diluted Weighted Average Shares | |||||
Basic EPS Including Extraordinary Items | |||||
Diluted EPS Including Extraordinary Items | |||||
Diluted EPS Excluding Extraordinary Items | |||||
Normalised Income Before Taxes | |||||
Normalised Income After Taxes | |||||
Normalised Income Available to Common Shareholders | |||||
Diluted Normalised EPS | 0 | 0 | 0 | 1.67 | -0.261 |